ost blood vessels are surrounded by fat, which led to the long-accepted belief that perivascular adipose tissue (PVAT) provides mechanical protection of the vessels during contraction of neighboring tissues, 1 evidenced by the arrangement of the perivascular tissues. Although the vessels sheaths and lamellae are formed by strong networks of collagen and elastic fibers, the perivascular area is filled by thin lamellae of connective tissue, delimiting the lobules of adipose tissue. 2 Until recently, the role of PVAT in the development of cardiovascular diseases and their consequences was considered to be passive, but recent studies, albeit still limited in scope, have unambiguously established that PVAT not only provides mechanical support for blood vessels, but also secretes large numbers of metabolically active adipokines, chemokines and hormone-like factors, such as leptin, adiponectin and resistin, free fatty acids, and vasoactive substances. 3 With both endocrine and paracrine actions, functional PVAT has effects on vascular tone regulation in physiological conditions in both rodents and humans. Importantly, the PVAT depot expands in obesity and in diabetes, in conjunction with the accumulation of inflammatory cells and a shift in the production of various adipokines and inflammatory cytokines, and we define the abnormal PVAT of these pathophysiological conditions as "PVAT dysfunction". Local secretion by dysfunctional PVAT of pro-atherogenic chemokines may provide a novel mechanistic link between obesity and associated vascular complications such as atherosclerosis. 4 In addition, an altered profile of adipokine and cytokine production by the PVAT of resistance arteries may also contribute to or modulate hypertension, but a causal role has yet to be established. Thus, PVAT is de facto emerging as a new functional vascular layer that plays an active role in the control of vascular (dys) function in (patho) physiological conditions ( Figure) .
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the regional white fat depots eventually form, and give rise to a resident self-renewing population of adipocyte progenitors. 9 Rodeheffer et al further demonstrated that white adipose stromal cell populations with expression of stem cell markers CD29 + :CD34 + :Sca-1 + :CD24 + are capable of spontaneous adipogenic differentiation in vitro. 10 In the same year, Tang et al identified that white adipose stromal cells, which express peroxisome proliferator-activated receptor-γ (PPARγ) and the mural-endothelial cell markers platelet-derived growth factor receptor-β, smooth muscle actin and chondroitin sulfate proteoglycan 4, were able to proliferate both in vivo and in vitro, underwent spontaneous adipogenesis in vitro and formed ectopic fat pads in nude mice. 11 Consistent with the expression of endothelial cell markers in stromal cells in the study of Tang et al, recent studies have suggested an endothelial origin for the adipocytes of white and brown adipose tissues (WAT and BAT, respectively), evidenced by a population of adipocyte stem cells from WAT and BAT expressing the endothelial marker VE-cadherin and VE-cadherin promoter-driven tracers, which are found in adipocytes from WAT and BAT. Also, the preadipocyte marker, zinc finger protein 423, is expressed in capillary endothelial cells within both types of adipose tissue from rodents and from capillary sprouts in human adipose tissue, which otherwise have predominantly endothelial cell characteristics. Sprouting cells become adipocytes with loss of endothelial characteristics after activation of PPARγ. 12, 13 The results of those studies suggest that the vasculature in adipose tissue harbors adipocyte progenitor cells, although, because of the intrinsic differences of the experimental models used, the specific nature of the progenitors remains elusive. However, it is likely that although adipose tissues share common differentiation origins (ie, MSCs) and pathways, adipose tissue in the different depots develops contextually through individual origins and pathways. For example, the adipocyte precursor cells isolated from mouse visceral and subcutaneous WAT have distinct gene expression patterns and differentiation properties. 14 Furthermore, a recent study suggested that fat cells might share the same differentiation origin with their neighboring organ. Seale et al reported that brown fat cells, but not white fat cells, arise from precursors that express Myf5, a gene previously thought to be expressed only in cells of myogenic lineage, 15 indicating a common origin between skeletal muscle cells and BAT. Interestingly, in a similar fashion, unexpected recent findings from our group suggest that the developmental origins of PVAT and vascular smooth muscle cells (VSMCs) are somehow linked. We found that the PVAT in the aortic and mesenteric regions is absolutely absent in a mouse model with PPARγ deletion in VSMCs obtained by crossing SM22α Cre knockin mice to PPARγ flox-tagged mice. However, it is interesting that both BAT and WAT were intact in mice with the PPARγ deletion in VSMCs, implying that PVAT, BAT and WAT have distinct origins. Although SM22α is an early marker of SMCs, 16 our results indicate that either SM22α is transiently expressed in Figure. Function and dysfunction of perivascular adipose tissue (PVAT). PVAT releases PVAT-derived relaxation factors, such as nitric oxide (NO), which act on the endothelium to relax. On the other hand, PVAT-derived contractile factors, such as angiotensin II (AngII), induce contraction. Both anticontractile and contractile factors released from PVAT help to maintain vascular tone. PVAT produces growth factors, such as herpetic growth factor (HGF), which leads to hyperplasia of smooth muscle cells. Additionally, macrophages in PVAT release inflammatory factors that lead to endothelial dysfunction, thus promoting atherosclerosis. On the other hand, thermogenesis by PVAT enhances clearance of plasma lipids and inhibits the development of atherosclerosis. aFGF, acidic fibroblast growth factor; IGFBP-3, insulin-like growth factor-binding protein-3; IL, interleukin; MCP, monocyte chemotactic protein; TNF, tumor necrosis factor; UCP-1, uncoupling protein-1. Paradoxical PVAT in CAD and HT precursor cells of PVAT harbored in the aorta or the precursor cells are common to PVAT and VSMCs. 17 Our studies also demonstrated that only PPARγ1 in VSMCs or common precursor cells is required for PVAT differentiation, evidenced by the presence of PVAT in PPARγ2 or PPARδ knockout mice. This unexpected finding suggests that the developmental origins of PVAT and VSMCs are somehow linked, perhaps through some proximal shared precursor cells, and that PVAT is unique and clearly different in its origin from that of other adipose depots.
White or Brown PVAT?
All types of adipose tissues contain adipocytes with abundant lipid droplets, macrophages, T cells, collagen fibers, capillaries and nerves. Traditionally, fat depots have been termed WAT or BAT according to the size of the lipid droplets and the number of mitochondria in the adipocytes. Adipocytes in WAT have a single, large lipid droplet and variable mitochondria, whereas those in BAT have multiple small vacuoles and abundant mitochondria. Visceral and subcutaneous adipose tissues are recognized as WAT, whereas adipose tissue in the interscapular region is considered as BAT in both rodents and human infants. Recently, BAT was found in the clavicular, cervical, suprarenal and periaortic regions of adult humans. 18 The main function of WAT is to store lipids, whereas that of BAT is to generate heat, and it is essential for adaptive thermogenesis and energy expenditure. However, the different depots of adipose tissue have distinct functions and it is now accepted that visceral adipose tissue is more harmful and associated with insulin resistance and cardiovascular events because of its greater inflammatory characteristics than subcutaneous adipose tissue, even though they are both traditionally classified as WAT. Furthermore, growing data demonstrate that the gene expression profiles differ between visceral and subcutaneous adipose tissues, indicating different physiological functions of these two WAT depots. Indeed, compared with visceral adipose tissue, which has an extremely low level of uncoupling protein-1 (UCP-1), UCP-1 mRNA is highly expressed in subcutaneous adipose tissue. Consistently, a large number of UCP-1 immunopositive cells reside in the subcutaneous adipose tissue of both rodents and humans, underlying the energy expenditure property of subcutaneous adipose tissue. Recently, a few hormones (ie, orexin, 19 irisin 20 ), genes (ie, phosphatase and tensin homolog, 21,22 placenta-specific gene 8, 23 T-box 15 24 ) and the drug, rosiglitazone, 25 have been reported as able to convert subcutaneous adipocytes to brownlike adipocytes, termed "beige" cells. Beige cells have a gene expression pattern that is distinct from either white or brown adipocytes, 26 but beige cells promote energy expenditure because of their high level of UCP-1 in mitochondria, similarly to classic brown adipocytes. In addition, the adipocytes in active BAT found in adult humans 18 may actually be beige cells, 26 which might be different from the classical adipocytes in the BAT of human infants. Nevertheless, the intrinsic characteristic of energy expenditure of BAT or beige adipocytes highlights the potential importance of these tissues as targets for treatment of obesity and related cardiovascular diseases.
Circulating adipokines released from adipose tissues are the mediators of the cross-talk between visceral or subcutaneous WAT and cardiovascular tissues. The most common of such adipokines are adiponectin, leptin and inflammatory factors such as interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) etc, which have all been well reviewed. 27 Most of the adipokines released from other adipose depots are found in PVAT as well. Importantly, PVAT is tightly attached to the vessel walls, and constitutes an integral layer of the vasculature. The communication between PVAT and the other layers of the vessel wall could happen locally through the vasa vasorum in the vessel walls, which is different from the action of other adipose tissues for which long-distance transportation of messengers is necessary. In addition, the activity of PVAT might directly feedback to the VSMCs or endothelial cells in a paracrine manner. Therefore, the anatomy and endocrine properties of PVAT highlight the intimate relationship between PVAT and vascular cells in terms of both physiological conditions, such as regulation of vessel tone, and pathophysiological conditions, such as vessel remodeling. Most importantly, several studies have suggested that PVAT has more characteristics of BAT than of WAT. PVAT displays similar morphological characteristics of BAT, with smaller, multilocular lipid droplets and abundant mitochondria in the adipocytes. Microarray mRNA analysis has revealed nearly overlapping gene expression patterns of BAT and PVAT in a rodent model, with equally high expression of UCP-1, Cidea, and other genes known to be uniquely or very highly expressed in BAT. 28 Our own study also found a striking similarity between thoracic PVAT and BAT on proteomic analyses. Functionally, consistent with the finding of triglyceride clearance by BAT under extreme cold stimulation, 29 we found that lipid clearance and maintenance of intravascular temperature were impaired in response to cold exposure in mice lacking PVAT. 17 Thus, PVAT is a distinct fat tissue in terms of its anatomical location, histological structure and molecular biology. The physiology of PVAT is more similar to that of BAT than WAT. Nonetheless, and keeping in mind the well-documented phenomena of differential functions of different WAT depots (ie, visceral vs. subcutaneous) and the differences in BAT across species, it remains to be determined whether PVAT differs from classical BAT, particularly in humans. Currently, the main focus of research in the field revolves around the functions of PVAT in vascular physiology, and, as reviewed next, the paradoxical findings on the roles of PVAT in the development of atherosclerosis and hypertension.
Paradoxical Roles of PVAT in Atherosclerosis
Pro-Atherosclerotic Properties of PVAT Atherosclerosis is a disease of the vasculature. The inflammatory response of the vessel wall is one of the major mechanisms that promote development of atherosclerosis. 30 Even though the plaque lesion is found in the media region of the vessel wall, growing evidence shows that the adventitia may contribute to vascular remodeling and constriction of the external elastic lamina through accumulation of myofibroblasts containing alpha smooth muscle actin in the adventitia surrounding the injury site. 31 Inhibition of myofibroblast proliferation and/or recruitment by intravascular brachytherapy positively affects vascular remodeling through action on adventitial cells. 32 Although the inflammatory response of the adventitia contributes to vascular remodeling, conversely the inflammatory response after arterial angioplasty occurs throughout the PVAT, 32,33 which suggests an intimate involvement of PVAT in vascular physiology and pathophysiology, consistent with the notion that PVAT constitutes an integral layer of the vasculature. Therefore, it is hypothesized that inflammatory cells in the PVAT may play a role in the recruitment and/or proliferation of adventitial myofibroblasts, and thus contribute to vascular remodeling. 33 Consistent with this hypothesis, endo-
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vascular injury significantly upregulates proinflammatory adipocytokines and downregulates adiponectin within PVAT after wire injury of the femoral artery of mice and balloon injury of the iliac artery in rats, 34 and a proinflammatory phenotype is found in murine PVAT after the feeding of a high-fat diet. 35 Indeed, compared with the secretory patterns of isolated adipocytes from human subcutaneous and visceral depots, the secretion of antiinflammatory adiponectin is markedly reduced while that of proinflammatory cytokines IL-6, IL-8, and monocyte chemotactic protein (MCP)-1 is markedly increased in coronary perivascular adipocytes. Likewise, 2 weeks of highfat diet increases proinflammatory gene expression in mouse PVAT without macrophage filtration. 35 The accumulation of macrophages and T cells at the interface between PVAT and the adventitia of human atherosclerotic aortas may reflect this pro-chemotactic activity of PVAT. 36 The relevance of local proinflammatory perivascular fat to the development of atherosclerosis was further established by experimental transplantation of fat to the mid-perivascular area of the common carotid arteries, which normally do not develop spontaneous atherosclerosis lesions, in apolipoprotein-E-deficient mice. Transplant of visceral WAT (inflammatory fat with increased macrophage content) resulted in enhanced atherosclerotic lesions combined with higher levels of serum MCP-1 and exacerbated endothelial dysfunction when compared with transplantation of subcutaneous WAT (endogenous non-inflammatory fat). 37 Likewise, the quantity of PVAT and extent of infiltration of macrophages are highly related to the size and composition of atherosclerotic plaque in patients with coronary atherosclerosis. 38 Additionally, in contrast with other fat cell types, PVAT cells release greater amounts of angiogenic factors (eg, herpetic growth factor (HGF), acidic fibroblast growth factor, thrombospondin-1, serpin-E1, MCP-1 and insulin-like growth factor-binding protein-3). 39 HGF is preferentially released by PVAT cells and stimulates endothelial cell growth and cytokine release from SMCs. Interestingly, only the PVAT mass, not the visceral or subcutaneous mass, correlates independently with serum HGF levels in patients, 39 implying that PVATderived HGF is important to vascular remodeling. In summary, higher levels of both angiogenic factors, such as HGF, and inflammation in PVAT may have pathological relevance, and may contribute to atherosclerotic plaque complications (Figure) . However, studies to date have not supplied direct causal evidence that enhanced inflammation and angiogenesis in PVAT contribute to development of atherosclerosis and it is clear that further extensive studies are required to tease out the role of PVAT in proatherogenic events.
Anti-Atherosclerotic Properties of PVAT
In general, besides vascular inflammation, development of atherosclerosis is associated with impaired energy metabolic status and endothelial dysfunction. 40 Temperature highly influences whole-body energy metabolic activity. 41 It is believed that metabolism in other organs could influence vessel energy metabolism. For example, BAT is essential for adaptive thermogenesis and energy expenditure in human infants. 42 PVAT has a BAT-like morphology, 17,28 implying that it may also have a BAT-like function. We reported that PVAT, similarly to BAT, is a heat-generating organ. PVAT is critical for the maintenance of intravascular temperature. 17 In mammals, changes in the environmental temperature induce vascular reactions, 43 which involve both endothelial and smooth muscle cell functions. This may occur in humans as well, in whom an increasing intravascular temperature gradient is formed in large veins as blood approaches the heart. 44 Associated evidence is that blood pressure (BP) in humans increases with cold or warm stimulation, 45 even though we do not know at this point whether this phenotype is associated with thermoregulation by PVAT. Similarly, it is unclear whether intravascular temperature can influence energy metabolism in the vessels and, consequently, further influence the development of atherosclerosis. Nevertheless, it is important to note that the local energy metabolism of the vessel wall influences vessel biology and further participates in the development of atherosclerosis. Considering that PVAT presents BAT-like characteristics, it can be proposed that high energy expenditure in PVAT will eventually affect vessel biology under pathological conditions. Our study demonstrated that PVAT could generate heat to maintain intravascular temperature. Furthermore, the levels of enzymes in PVAT that are related to metabolic processes were increased when mice were housed at 16°C, suggesting activation of PVAT in this mildly cold environment. As a result of the activation of PVAT, the development of atherosclerosis was attenuated in that experimental model. Importantly, plasma triglyceride levels were also reduced in mice at 16°C, even though the BAT had been surgically removed. Therefore, fewer atherosclerotic lesions in a cold environment might be a consequence of enhanced total lipid clearance by the thermogenic activation of PVAT. In support of this conclusion, the atherosclerotic burden in mice lacking PVAT was increased even when the mice were housed in cold conditions. To date, it is clear that active BAT exists in the peri-aortic region of adult humans living in cold climates, 46 and that activation of BAT 29 and PVAT 17 with cold exposure increases triglyceride clearance in rodents. However, it is uncertain whether cold exposure could reduce plasma cholesterol levels, and in turn inhibit development of atherosclerosis in humans. Clinical observations indicate that both extreme hot and cold acclimation increase the rate of mortality from heart attacks. We need extensive, well-controlled studies from the clinical arena to clarify whether cold exposure is beneficial in preventing the development of atherosclerosis in humans.
Inflammation of the vasculature enhances the development of atherosclerosis, although we found that the enhanced inflammation in the PVAT of mice fed a high-fat diet was not reduced when the animals were housed in a cold environment, indicating that enhanced clearance of plasma triglycerides was more likely to contribute to the reduced atherosclerosis in these mice. 17 Fitzgibbons et al showed that C57BL/6J mice fed a high-fat diet exhibited relatively less inflammation in both PVAT and BAT compared with WAT. 28 Thus, the results of those studies suggest that the thermogenic properties of PVAT from the thoracic aorta may play an important role in protecting the vascular bed from inflammatory stress.
In conclusion, PVAT appears to play a paradoxical role on atherogenesis. On the one hand, as extensively reviewed previously, 47 it is clear that increased inflammation, a known proatherogenic factor enhancing development of atherosclerosis in animal models, occurs in the PVAT upon high-fat diet challenge. Similarly, injury to the inside of the vessels also enhances inflammation in the PVAT, highlighting the intrinsic inflammatory reactivity of this adipose depot. On the other hand, similarities between the PVAT and BAT in rodents and beige fat in humans indicate that the thermogenetic property of PVAT, paired with its ability to clear plasma triglycerides, could inhibit development of atherosclerosis, as recently found in our model. 17 This paradoxical effect of PVAT resulting in either pro-or anti-atherogenesis, the factors that tip the balance in either direction and the potential use of this property of PVAT in therapeutic or preventive interventions need to be Paradoxical PVAT in CAD and HT further investigated using animal models lacking PVAT.
Paradoxical Roles of PVAT in Hypertension
Hypertension is a complex vessel disease in which multiple mechanisms are involved, with the vessel wall as the final effector in the regulation of BP. Vascular bioactive substances act on either the endothelium or SMCs to regulate the tension of the vessel wall. Here, we will focus only on BP regulatory substances released from PVAT.
Anticontractile Effects of PVAT
PVAT is firmly attached to the adventitia of vessels and similar to other depots of adipose tissue, it acts as an endocrine organ, releasing a wide range of biologically active molecules that modulate VSMC contraction, proliferation and migration. Conversely, inflammatory responses after intravascular injury occur throughout the entire perivascular tissue. 33 These findings strongly indicate that communication flows bi-directionally between other components of the blood vessel wall and PVAT. In support of this hypothesis, accumulating evidence indicates that PVAT exerts anticontractile effects in various vascular beds, a phenomenon that seems to be mediated by as yet unknown PVAT-derived relaxing factors (PVRF). This anticontractile effect of PVAT is impaired in disease conditions such as metabolic syndrome 48-53 and hypertension, 48,54-57 further underscoring the physiological role of PVAT in vascular tone. However, not 1 PVRF has been definitively identified to date. It has been proposed that PVRF might comprise adiponectin, 58,59 H2S, 60 NO, 61 and angiotensin (Ang) 1-7. 62 Most recently, palmitic acid methyl ester was determined to function as a PVRF, causing vasorelaxation by opening voltagedependent K + channels in SMCs. 63 We further demonstrated that prostacyclin released from PVAT might be a vasoactive PVRF. 17 Prostacyclin is a potent vessel dilator synthesized in endothelial cells. 64 However, prostacyclin is readily detectable in PVAT and could be released into an incubation solution. 17 It is well established that impaired function of COX2 is involved in acetylcholine-induced vessel constriction, an indication of endothelial dysfunction, in aging and hypertensive subjects. 65 Our data demonstrated that incubation with PVAT completely blocked the acetylcholine-induced constriction of vessel rings isolated from aging mice, but pre-incubation of the vessel rings with a prostacyclin receptor antagonist significantly blunted the effects of PVAT on acetylcholine-treated vessel rings, 17 thus reinforcing that PVAT-derived prostacyclin targets other vascular cells to reduce contractility and defining it as a newly identified PVRF.
Regarding the possible underlying mechanisms, PVRF might induce endothelium-dependent relaxation through release of nitric oxide (NO) and subsequent K + channel activation. This was evidenced by relaxation of aortic rings, in which PVAT was removed, induced by transference into an incubation solution with PVAT. The PVAT-dependent relaxation was abolished by endothelial cell removal, NO synthase inhibition, scavenging of NO, high extracellular K + , or blockade of calcium-dependent K + channels. 61 Apart from opening the K + channels in the endothelium and/or SMCs, PVRF might exert their anticontractile effects through endothelium-independent mechanisms involving H2O2 and subsequent activation of guanylyl cyclase (sGC). 61 In aortic rings with removal of the endothelial layer, the contraction in response to phenylephrine of rings with intact PVAT, but not of those without PVAT, was enhanced by catalase or sGC inhibitors, but reduced by superoxide dismutase and iron. Additionally, NO donors and H2O2 exhibited additive inhibition of the contraction to phenylephrine by aortic rings after removal of both PVAT and the endothelium. 61 However, most of these studies have been performed using isolated vessel rings (either from the thoracic aorta or mesenteric artery of rodents) in the presence or absence of the PVAT layer in ex vivo experimental conditions. It should be noted that under such experimental conditions, the vessel beds used in the stimulation tests are not readily comparable. The presence of PVAT in 1 vessel ring and not in another will result in the afterload of the vessel ring without PVAT being less than that of the vessel ring with PVAT under the conditions of drug stimulation (eg, adrenaline, etc). Therefore, the conclusions of the anticontractile effect of PVAT on vessels still remains to be further studied using more precise and biologically relevant experimental conditions and animal models.
Contractile Effects of PVAT
Apart from the existence of anticontractile PVRF in PVAT, it is to be highlighted that PVAT-derived contractile factors are also found. Recent studies have demonstrated that all components of the renin-angiotensin system, except renin, can be detected in PVAT. 64 In addition, 3 isoforms of the AT(1a) receptor have been found in PVAT, and a very low expression of the AT(1b) has also been found. 66 Although electrical stimulation elicited a frequency-dependent contraction in rings from intact vessels with the PVAT layer, vessel rings devoid of PVAT showed no response. Phentolamine blocked the contractile responses generated by these manipulations, which activate the sympathetic neuroeffector system. Responses evoked by electrical stimulation in intact vascular preparations were significantly attenuated by prior exposure to the selective AngII antagonist, SarI-Ile8-AII. 67 Treatment of rat mesenteric artery vessels with enalaprilat, an angiotensin-converting enzyme inhibitor (ACEI), reduced the PVAT-mediated potentiation of contraction induced by electrical stimulation. Exogenously applied AngII enhanced contraction in arteries without PVAT when induced by electrical stimulation, but not in arteries with intact PVAT. Chronic treatment with the ACEI, quinapril, alleviated the potentiation effects of PVAT on contraction induced through electrical stimulation. These results imply that PVAT-derived AngII is critically involved in PVATmediated potentiation of electrical stimulation-evoked contraction in arteries. 68 Norepinephrine (NE) is detected in both BAT and PVAT, and dopamine-β-hydroxylase in BAT has been reported. 69 Consistent with the existence of NE in BAT, minced PVAT or BAT strongly induces vessel ring constriction in vitro, 17 and antagonists of alpha-adrenergic receptors effectively block PVAT-or BAT-induced constriction of vessel rings (unpublished data). Furthermore, Gao et al showed that PVAT enhanced the mesenteric arterial contractile response to perivascular nerve stimulation through the production of superoxide mediated by NAD(P)H oxidase, and that this enhancement involved activation of tyrosine kinase and the MAPK/ERK pathway. 70 These observations demonstrate that PVAT significantly contributes to constriction of the aorta in ex vivo settings. Furthermore, the contractile effects of PVAT might partially explain the hypotensive phenotype in the mouse models lacking PVAT that we describe later.
BP in Animal Models With Reduced or Absent PVAT
To date, direct evidence from animal models to support the notion of an anticontractile role for PVAT in the regulation of BP is missing. There are only 3 published rodent models with reduced or absent PVAT. CHANG L et al.
One is the A-ZIP/F mouse, which was generated by expressing a dominant-negative protein termed A-ZIP/F under the control of the adipose-specific aP2 promoter. A-ZIP/F mice have no WAT, dramatically reduced amounts of BAT, and reduced PVAT throughout their lifespan. These animals have complicated physiological consequences of the lack of WAT, including diabetes 71 and hypertension. 48, 72 Removal of the remnants of PVAT from the aortas of A-ZIP/F mice resulted in a higher contractile response to AngII when compared with aortas from wild-type mice after the removal of PVAT. Conversely, transfer to and incubation in a solution of wild-type PVAT added to the aorta devoid of PVAT caused a relaxation response in wild-type mice, but not in A-ZIP/F1 mice. 46 However, there is no direct evidence to support that the PVRF cause this phenomena rather than a change in the aorta itself in A-ZIP/F mice. This is suggested by reported higher expression levels of AT1 receptors, but not AT2 receptors, in the aortas of A-ZIP/F compared with those of WT mice. 48 Another mouse model is the MORE-PGKO. 72 MORE-PGKO mice are rescued from the embryonic lethality of global PPARγ knockout by breeding Mox2-Cre (MORE) mice with floxed PPARγ mice to inactivate PPARγ in the embryo but not in the trophoblasts. MORE-PGKO mice lack interscapular BAT, as well as mesenteric, perirenal, subcutaneous, epididymal and periovarian fat. In addition to a phenotype of severe lipodystrophy and insulin resistance, MORE-PGKO mice are hypotensive. Their VSMCs have impaired contraction in response to stimuli by α-adrenergic agents. Additionally, the reninangiotensin-aldosterone system is mildly activated. These effects are likely mechanisms contributing to the observed hypotension, 72 although no information is currently available regarding the status of the PVAT in these animals.
We generated a third model, known as SMPG KO mice, through PPARγ deletion in VSMCs via an SM22α-Cre knockin strategy. 17 Unlike the A-ZIP/F and MORE-PGKO mice, SMPG KO mice display normal glucose metabolism, development of WAT and interscapular BAT, but they exhibit complete loss of PVAT. Consistent with the MORE-PGKO mice, SMPG KO mice present hypotension in the resting period of the circadian cycle. However, it is unclear whether loss of PVAT in these mice causes hypotension because the expression levels of the β-adrenergic receptor are increased as a result of PPARγ deletion in their SMCs. 17 Arguing against the idea that the hypotensive phenotype of SMPG KO mice is caused by PPARγ deletion in VSMCs, another 2 published mouse models show a hypertensive phenotype when the PPARγ level or function in VSMCs is altered using different strategies. One is PPARγ deletion in VSMCs using an SM22α-Cre transgenic strategy; 73 another is transgenic mice (S-P467L) expressing the protein-coding sequence of human PPARγ1 carrying the P467L mutation under the control of a smooth muscle myosin heavy chain (SMMHC) promoter. S-P467L mice exhibit a loss of responsiveness to NO and striking alterations in the contractility of the aorta, as well as systolic hypertension. 74 It is notable that PVAT is present in both of these PPARγ mouse models.
Thus, comparing the 4 mouse models with PPARγ deletion in VSMCs, it seems that the effects on BP are associated with the presence of PVAT (ie, hypotensive in models lacking PVAT and hypertensive in models that preserve PVAT). However, no model to date is perfect and they all have limitations when used to evaluate the effects of PVAT on the regulation of BP. Both the A-ZIP/F and MOPG KO mice have severe lipodystrophy and insulin resistance, which would affect BP. Even though the SMPG KO mice have normal systemic metabolism and differentiation of other adipose tissue depots, concurrent PPARγ deletion in VSMCs is a major limitation to determining the specific effects of PVAT on vasoactivity in vivo. A new animal model in which only PVAT is removed without additional disturbance to the genome, the expression profiles or development of other tissues in the body should be developed. Even though we have a mouse model with complete lack of PVAT, the major limitation of concurrent PPARγ deletion in VMSC, as already mentioned, is interference with the precise interpretation of the data. It is clear that only PPARγ1 is essential for differentiation and development of PVAT in vivo. The challenge is how to target deletion of PPARγ1 in PVAT and, consequently, block differentiation of PVAT. As we have already reviewed, PVAT might be differentiated from VSMCs, introducing a limitation that cannot be ignored when using Cre strategies as a tool. Use of a SMC-selective promoter driving Cre will result in PPARγ1 deletion in VSMCs, as in our model. How to drive PVAT-specific transgenesis or Cre knockin is an issue that needs to be further refined. Therefore, we need to systematically explore specific genes that are only expressed in brown preadipocytes in rodents, in order to make a suitable Cre tool to advance our understanding of the multiple and paradoxical roles of PVAT. Strictly speaking, we have to acknowledge that PVAT in humans and other large animals, such as the pig or rabbit, might be beige fat tissue, which is not identical to brown adipocytes. Therefore, it will still be a challenge to translate the findings of mice models to humans. The next frontier in the field will be to find a specific gene in beige cells to make a suitable Cre tool and develop representative animal models in rabbits or pigs.
Perspective
The general view is that the vascular wall consists of 3 layers: the tunica intima, tunica media and tunica adventitia. As summarized in this and other reviews, 27 PVAT is an active connective tissue that surrounds the vessels and releases vasoactive substrates that affect vascular function while, in turn, responding to signals from the endothelium and smooth muscle cells. Therefore, PVAT (layer 4 that we designate as adipotima) constitutes a distinct functional compartment of the vascular wall, and cannot be excluded when investigating the physiology and pathophysiology of the vasculature, any more than the endothelium or smooth muscle cells. However, for a long time PVAT did not attract attention, until Soltis and Cassis reported its influence on rat aortic smooth muscle responsiveness in 1991. 67 Many studies and reviews predicted that inflammation of the PVAT might promote development of atherosclerosis and that the anticontractile effect of PVAT might benefit hypertension. Now PVAT is recognized as a distinct adipose tissue that releases both inflammatory and antiinflammatory factors, and both contractile and anticontractile factors, among a plethora of other paracrine factors, ensuring vessel homeostasis. This phenomenon is similar to that observed for other components of the vascular wall; for instance, NO and endothelin-1 are both released from the endothelium to relax or contract the vascular wall. Therefore, it would be simplistic and physiologically inaccurate to define PVAT simply as a support tissue or to label it as "bad" or "good" for the vasculature. According to current studies, the existence of more fat, including PVAT, in the different depots in the body is harmful to health, underscoring the important homeostatic roles of all these fat depots. Thus, for example, insulin resistance and hypertension are found in both obese mice (ob/ob, diet-induced obese mice, etc) and mice without Paradoxical PVAT in CAD and HT fat (A-ZIP/F mice). The abnormal properties of PVAT in pathophysiological conditions could be defined as "PVAT dysfunction", and the normal PVAT in physiological condition could be defined as "functional PVAT". Nevertheless, to determine the roles of functional PVAT and PVAT dysfunction on the vasculature and neighboring tissues, it will be necessary to use PVAT-deficient animal models under physiological or pathophysiological conditions, such as obesity-associated diseases, atherosclerosis, hypertension, and diabetes. As our knowledge of PVAT function increases through the development of the necessary animal models and technologies, cell-specific gene interventions and local treatments may provide further evidence for the identification of novel key factor(s) involved in PVAT (dys) function in the vasculature and vascular disease. Targeting this vascular layer may prove useful in developing novel single or combined therapeutic or preventive strategies for cardiovascular diseases.
